AI assistant
PDS Biotechnology Corp — Director's Dealing 2017
May 9, 2017
34613_dirs_2017-05-09_8bc61431-b549-4e60-ab67-b779076238f4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2017-04-26
Reporting Person: Leuthner Brian A (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-04-26 | Common Stock | S | 100 | $11.10 | Disposed | 135236 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 162000 | Indirect |
| Common Stock | 223622 | Indirect |
Footnotes
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed as an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.